-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Reiterates Market Outperform on Summit Therapeutics, Maintains $40 Price Target

Benzinga·01/30/2026 14:25:45
Listen to the news
Citizens analyst Reni J. Benjamin reiterates Summit Therapeutics (NASDAQ:SMMT) with a Market Outperform and maintains $40 price target.